|
Reconciliation of Non-GAAP Adjusted EPS Guidance |
Guidance |
||||||||||||||||||||||||
|
Q2 2023 |
Full Year 2023 |
||||||||||||||||||||||||
|
(unaudited) |
Per Share |
Per Share |
|||||||||||||||||||||||
|
GAAP diluted earnings per share guidance |
$1.30 – $1.70 |
$7.75 – $8.75 |
|||||||||||||||||||||||
|
Estimated adjustments |
|||||||||||||||||||||||||
|
Other (a) |
$ — |
$ — |
|||||||||||||||||||||||
|
Adjusted diluted earnings per share guidance |
$1.30 – $1.70 |
$7.75 – $8.75 |
|||||||||||||||||||||||
GSK’s Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a significant improvement in progression-free survival for relapsed or refractory multiple myeloma compared to bortezomib with PomDex.
